We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 13.50
Ask: 14.50
Change: -0.50 (-3.45%)
Spread: 1.00 (7.407%)
Open: 14.50
High: 14.50
Low: 14.00
Prev. Close: 14.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Fevertree lowers guidance; DP Poland sales rise

Fri, 15th Jul 2022 11:21

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Ncondezi Energy Ltd, up 91% at 1.48 pence, 12-month range 0.004p-1.90p. The Mozambique-based power developer says it has launched a feasibility study for a 300 megawatt solar photovoltaic power plant and battery energy storage system. The study will require four months to be completed and will be funded through available capital after completing the restructuring of the Seritza term loan. The solar project will be located within the Ncondezi concession area, with three sites identified, and have an estimated pre-money net present value between USD60 million and USD65 million.

----------

N4 Pharma PLC, up 21% at 2.85 pence, 12-month range 2.02p-10.43p. In a pre-clinical study of delivery system Nuvec with TNF-alpha, known as Medicines Discovery Catapult, there is clear tumour suppression with 10 micrograms of TNF-alpha loaded into Nuvec, a lower dose than used in earlier studies. Biochemical analysis of blood and tissue samples show that treatment led to an increase in circulating plasma TNF-alpha levels. "We continue to make good progress in understanding how Nuvec can be used in the oncology space," says CEO Nigel Theobald.

----------

Novacyt SA, up 8.5% at 116.99 pence, 12-month range 1.06p-123.77p. The clinical diagnostics firm says its 'exsig' Covid-19 direct real-time PCR test has been approved in the UK under the the UK Health Security Agency's coronavirus test device approvals regulations. The test "removes the need for manual or automated extraction solutions to significantly improve laboratory workflow and reduce costs".

----------

DP Poland Ltd, up 6.9% at 6.20 pence, 12-month range 5.00p-9.00p. The franchise in Poland for Domino's Pizza said system sales were significantly above pre-Covid levels in June. The company saw like-for-like system sales increased by 24% compared to a year ago and by 23% compared to June 2019. Total system sales were up by 21% compared to June 2021 and 15% compared to June 2019. In the first 10 days of July, LFL system sales increased by 33% on a year before.

----------

AIM - LOSERS

----------

Fevertree Drinks PLC, down 27% at 869.50p, 12-month range 804.50p-2,871.00p. In the first half of 2022, the premium tonic water maker posts revenue of GBP160.9 million, up 14% from GBP141.8 million year-on-year. UK sales rise 6% to GBP53.5 million and US sales increase 11% to GBP40.1 million, while total Europe revenue jumps 27% to GBP52.4 million. However, Fevertree now expects earnings before interest, tax, depreciation and amortisation in a range of GBP37.5 million to GBP45 million, down from a prior range of GBP63 million to GBP66 million. In 2021, the company achieved Ebitda of GBP63.0 million. The company flags labour shortages in the US, resulting in greater UK production, which means greater exposure to increasing sea freight rates. In addition, glass availability has become "severely restricted" and industry-wide cost pressures, such as glass, have increased.

----------

Angle PLC, down 12% at 82.20 pence, 12-month range 71.70p-163.75p. The Surrey, England-based medical diagnostics company raises GBP20.1 million through the issue of 25.2 million shares via a placing, retail offer and subscription at a price of 80 pence per share, reflecting a 14% discount to Thursday's closing price at 93.50p. Net proceeds will be used to help its commercialisation plans for its Parsortix system. Now has 260.5 million shares issued overall.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
24 Apr 2024 17:06

CORRECT: No record close for FTSE 100; mixed trade in US

(Correcting day of the week in the opening sentence.)

Read more
24 Apr 2024 17:00

LONDON MARKET CLOSE: No record close for FTSE 100; mixed trade in US

(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
22 Apr 2024 16:52

IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide

Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells.

Read more
22 Apr 2024 06:59

Angle granted European patent for CellKeep, US patent imminent

(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.

Read more
22 Jan 2024 18:03

IN BRIEF: Angle highlights supportive data for DNA analysis tool

Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.

Read more
4 Jan 2024 16:54

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

Read more
4 Jan 2024 12:19

Angle shares soar following "breakthrough" cancer diagnostics results

(Alliance News) - Angle PLC on Thursday said that "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Read more
4 Jan 2024 12:09

LONDON MARKET MIDDAY: Retailers Next and JD Sports bookend FTSE 100

(Alliance News) - Stock prices in London were slightly higher at midday on Thursday, with the FTSE 100 looking set to snap the two-day losing streak it suffered at the start of the year.

Read more
4 Jan 2024 10:43

AIM WINNERS & LOSERS: Angle soars on clinical tests; Likewise sales up

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
4 Jan 2024 08:58

LONDON MARKET OPEN: Next leads buoyant FTSE 100 amid services PMIs

(Alliance News) - Stock prices in London opened up on Thursday, amid a slew of services PMI data, including for the UK, while reacting to the latest data from China.

Read more
4 Jan 2024 07:58

Angle receives 'breakthrough results' from DNA molecular analysis

(Sharecast News) - Liquid biopsy company Angle received "breakthrough results" from DNA molecular analysis of cancer patient blood samples on Thursday, sending its shares skywards as a result.

Read more
2 Jan 2024 09:04

Angle locks in $250,000 contract with Eisai

(Sharecast News) - Liquid biopsy company Angle has locked in a $250,000 contract with global pharmaceutical company Eisai to deliver circulating tumour cell analysis in a pilot study.

Read more
2 Jan 2024 08:51

IN BRIEF: Angle teams with Japan's Eisai in breast cancer drug trial

Angle PLC - Surrey, England-based medical diagnostics - Signs contract with Eisai Inc, part of Tokyo-based pharmaceutical firm Eisai Co Ltd. Under the agreement, the two will engage in a pilot study worth USD250,000 to Angle. Angle will provide circulating-tumour-cells analysis using its Portrait HER2 assay to assess the response of breast cancer patients to Eisai's BB-1701 antibody-drug conjugate. BB-1701 targets HER2, a protein that speeds up the growth of breast cancer cells. Success in the phase two pilot study will offer the possibility for multiple follow-up studies.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.